Arthi Thirumalai
Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1679800932
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,441 of the $2,688 with a category attached, or 90.8%. Novo Nordisk accounts for 96.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $2,566, more than ten times the $39 reported in 2020.
Across 7 payments — averaging $383.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Abbott$50
- Esperion Therapeutics, Inc.$39
Across 11 payments — averaging $11,507 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$125K
- Eli Lilly$2K
What the payments were for
- Consulting fees$2,44191%
- Food & beverage$1646%
- Education$321%
- Other$502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $2,599 |
| Abbott | 1 | $50 |
| Esperion Therapeutics, Inc. | 2 | $39 |
How this compares
$2,688 in reported general payments places this provider in the 65th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $135,691 |
| MounjaroTirzepatide | 77 | $100,490 |
| JardianceEmpagliflozin | 57 | $85,600 |
| Repatha SureclickEvolocumab | 64 | $71,225 |
| TrulicityDulaglutide | 21 | $36,788 |
| FarxigaDapagliflozin Propanediol | 11 | $14,328 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $11,834 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $10,548 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $8,028 |
| Novolog FlexpenInsulin Aspart | 26 | $5,720 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $5,463 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $4,027 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 22 | $3,063 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 19 | $2,690 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 11 | $1,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,599 | $135,69173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Seattle
- Irl HirschSeattle$192K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- William HagopianSeattle$30K
- Mahnaz MellatiSeattle$28K
- Alan ChaitSeattle$21K
- Jose GarciaSeattle$12K
- Carla GreenbaumSeattle$7K
- Tracy TyleeSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.